Effectiveness of Platelet Function Analysis-Guided Aspirin and/or Clopidogrel Therapy in Preventing Secondary Stroke: A Systematic Review and Meta-Analysis.
Ann-Rong YanMark NauntonGregory Mark PetersonIsrael Fernandez-CadenasReza MortazaviPublished in: Journal of clinical medicine (2020)
The two studies showed opposite effects of PFA-guided ATM on the recurrent strokes in aspirin non-responders, leading to an insignificant difference in the subgroup meta-analysis (OR 1.59; 95% CI 0.07 to 33.77), while the rates of any bleeding events (OR 1.04; 95% CI 0.49 to 2.17) or death from any cause (OR 1.17; 95% CI 0.41 to 3.35) were not significantly different between aspirin non-responders with ATM and those without ATM. There is a need for large, randomized controlled trials which account for potential confounders such as ischemic stroke subtypes, technical variations in the testing protocols, patient adherence to therapy and pharmacogenetic differences.
Keyphrases
- low dose
- antiplatelet therapy
- systematic review
- dna damage
- atrial fibrillation
- randomized controlled trial
- dna repair
- cardiovascular events
- dna damage response
- acute coronary syndrome
- meta analyses
- percutaneous coronary intervention
- case control
- case report
- cardiovascular disease
- clinical trial
- type diabetes
- stem cells
- mesenchymal stem cells
- skeletal muscle
- oxidative stress
- insulin resistance
- cell therapy
- risk assessment
- open label
- phase iii
- blood brain barrier
- cerebral ischemia
- glycemic control
- brain injury
- weight loss